País: Austràlia
Idioma: anglès
Font: Department of Health (Therapeutic Goods Administration)
erythromycin lactobionate, Quantity: 1.49 g (Equivalent: erythromycin, Qty 1 g)
Panpharma Australia Pty Ltd
Injection, powder for
Excipient Ingredients:
Intravenous
1, 10, 25
(S4) Prescription Only Medicine
Oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,Erythromycin Panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time.,? Upper respiratory tract infections caused by Streptococcus pyogenes (Group A beta-haemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? Lower respiratory tract infections caused by Streptococcus pyogenes (Group A beta-haemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae).,? Respiratory tract infections due to Mycoplasma pneumoniae.,? Skin and skin structure infections caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment).,? Diphtheria - As an adjunct to diphtheria antitoxin in infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers.,? Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: Erythromycin Panpharma (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin.,? Before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for T. pallidum (by immuno-fluorescence or dark field) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter.,? Legionnaires' disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' disease.
Visual Identification: A white or slightly yellow powder.; Container Type: Vial; Container Material: Glass Type III Clear; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2018-10-18
[MEDICINE NAME] ® ™ 1 ERYTHROMYCIN PANPHARMA _erythromycin 1 g (as lactobionate) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about ERYTHROMYCIN PANPHARMA. It does not contain all the available information. It does not take the place of talking to your doctor or nurse. All medicines have risks and benefits. Your doctor has weighed the risks of you taking ERYTHROMYCIN PANPHARMA against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR NURSE. KEEP THIS LEAFLET. You may need to read it again. WHAT ERYTHROMYCIN PANPHARMA IS USED FOR ERYTHROMYCIN PANPHARMA contains erythromycin, an antibiotic that belongs to the group of medicines called macrolides. These medicines work by killing or stopping the growth of bacteria that cause infections. ERYTHROMYCIN PANPHARMA is used to treat certain bacterial infections. These infections may occur in different parts of the body. ERYTHROMYCIN PANPHARMA will not work against infections caused by viruses, such as colds or flu. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine is available only with a doctor's prescription. BEFORE YOU ARE GIVEN ERYTHROMYCIN PANPHARMA TELL YOUR DOCTOR IF YOU HAVE ANY OF THE FOLLOWING CONDITIONS OR IF YOU HAVE EVER EXPERIENCED ANY OF THESE CONDITIONS. It is very important that your doctor is aware of these matters when determining whether or not to prescribe ERYTHROMYCIN PANPHARMA. _WHEN YOU MUST NOT BE GIVEN _ _ERYTHROMYCIN _ _PANPHARMA _ YOU MUST NOT BE GIVEN ERYTHROMYCIN PANPHARMA IF YOU HAVE AN ALLERGY TO: • any medicine containing erythromycin • any of the ingredients listed at the end of this leaflet. • other from the macrolide family, including: − clarithromycin − roxithromycin Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swel Llegiu el document complet
ERYTHROMYCIN PANPHARMA (erythromycin lactobionate) Version 1.3 1 of 20 AUSTRALIAN PRODUT INFORMATION – ERYTHROMYCIN PANPHARMA (ERYTHROMYCIN LACTOBIONATE) POWDER FOR INJECTION 1 NAME OF THE MEDICINE Erythromycin lactobionate. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Erythromycin Panpharma is available as a sterile, lyophilized cake for reconstitution containing the equivalent of 1 g erythromycin activity. Erythromycin is produced by a strain of _Streptomyces erythraeus_ and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. Erythromycin Panpharma (sterile erythromycin lactobionate) is a soluble salt of erythromycin suitable for intravenous administration. The main component is erythromycin A lactobionate. 3 PHARMACEUTICAL FORM Powder for injection. For intravenous infusion following reconstitution and dilution. 4 CLINICAL PARTICULARS 444 4444444444444444444444444 Oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. Erythromycin Panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. • Upper respiratory tract infections caused by _Streptococcus pyogenes_ (Group A beta-haemolytic streptococci); _ Streptococcus pneumoniae_ (_Diplococcus _ _pneumoniae_); _Haemophilus influenzae_ (many strains of _H. influenzae_ are not susceptible to the erythromycin concentrations ordinarily achieved). • Lower respiratory tract infections caused by _Streptococcus pyogenes_ (Group A beta-haemolytic streptococci); _ Streptococcus pneumoniae_ (_Diplococcus _ _pneumoniae_). • Respiratory tract infections due to _Mycoplasma pneumoniae_. • Skin and skin structure infections caused by _Streptococcus pyogenes_ an Llegiu el document complet